Remove

Under the Paperwork Reduction Act of 1995, no persons are required to respon

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10040315			
Filing Date		2001-10-29			
First Named Inventor Fares Art Unit Examiner Name Hutse		50 50			
		1652			
		on, Richard			
Attorney Docket Number		UCAL-105CIP2			

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date		Name of Patentee or Applicant		Columns,Lines where ant Passages or Relev s Appear	
	1	6607893		2003-08-19	Warner-Lan	Warner-Lambert Company			
	2	6552250		2003-04-22	Nykiforuk et	Nykiforuk et al.			
	3	7015373		2006-03-21	Zou et al.				
If you wis	h to a	dd additional U.S. Pater	t citatio	n information	please click th	e Add button.		Add	
			U.S.P	ATENT APP	LICATION PU	BLICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	ication Number Kind Publication Name of Patentee of Applicant Re		Releva	Columns,Lines where ant Passages or Relev s Appear			
	1	20060090222		2006-27-04	Zou et al.	Zou et al.			
	2	20050193446		2005-09-01	Zou et al.				
If you wisi	h to a	dd additional U.S. Publi:	shed Ap	plication cital	tion information	please click the Ad	d button	Add	_
				FOREIGN P	ATENT DOCU	MENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		d Publication le ⁴ Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	TS

U.S.PATENTS

	1									
If you wis	h to a	dd add	ditional Fore	ign Pati	ent Document	citation	information pl	ease click the Add butto	n Add	
					NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Initials* No look, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Ts			
	1									
If you wish	h to a	dd add	ditional non-	patent I	terature docu	ment ci	tation informat	on please click the Add	button Add	
					E	AMINE	R SIGNATUR	E		
Examiner	Signa	ture						Date Considered		
*EXAMIN	ER: Ir	itial if	reference o	onsider	nd. whether o	r nat cit	ation is in conf	ormance with MPEP 609	Draw line through a	

See Kink Codes of USPTO Patent Documents at Invent/LEPTO_CODY or MPEP 901.04. Enter office that issued the document, by the Nov-letter option Shandard ST3.) For Legarages patent document, the profit and on the year of the region or preceded to see an under the Depart document. A for other patent document, the contraction of the year of the region for the Emperor many preceded to see an under the patent document. If which of coursent by the appropriate symbols as indicated on the document under WIPO Shandard ST.16 if possible, Sppicant is to place a check mark here if Employin languages the resistance in attached.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10040315		
Filing Date		2001-10-29		
First Named Inventor	Farese			
Art Unit		1652		
Examiner Name Hutso		on, Richard		
Attorney Docket Number		UCAL-105CIP2		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information sidelosure statement. See 37 CFR 197(e)(1).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, to father of information contained in the information disclosure statement was known to any order of the property of the property of the information disclosure statement. See 37 CFR 1.97(40).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

□ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Paula A. Borden/	Date (YYYY-MM-DD)	2006-05-17
Name/Print	Paula A. Borden	Registration Number	42344

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is foll field and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 37 CFR.

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, and Superiment of Commence, P. 0. Bot 1450, Alexandria, V.32.211-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, V.32.231-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a pleath pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via stife of manaplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.